Medical Doctor Program year 2019 Source: CMS Open Payments, 2026 publication

Mohsen Ehsan

Rheumatology New Albany, IN Medical Doctor

NPI 1669560215 CMS profile 496303

1919 State St Ste 244, New Albany, IN 47150

Open in the dashboard

General payments

$2,322

144 records reported · program year 2019

Research payments

$0

Paid to them · None reported · program year 2019

Ownership & investment interest

$0

None reported

Through program year 2019, Mohsen Ehsan of New Albany, IN is reported in the CMS Open Payments database as having received $2,322 across 144 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 49th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2019 General $2,322 144

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mohsen Ehsan
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Mohsen Ehsan were reported at $0. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Mohsen Ehsan Rheumatology median Middle half National median
2019 $2,322 $744 $153–$2,687 $163
2020 $0 $462 $98–$2,027 $114
2021 $0 $531 $101–$2,153 $132
2022 $0 $627 $125–$2,303 $149
2023 $0 $741 $145–$2,524 $160
2024 $0 $830 $166–$2,660 $164
2025 $0 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program year 2019
  1. Amgen Inc. $635 39 payments
  2. AbbVie, Inc. $317 18 payments
  3. UCB, Inc. $166 11 payments
  4. Novartis Pharmaceuticals Corporation $147 10 payments
  5. Mallinckrodt Enterprises LLC $138 7 payments
  6. Lilly USA, LLC $130 16 payments
  7. Radius Health, Inc. $116 2 payments
  8. Regeneron Healthcare Solutions, Inc. $98 5 payments
  9. Janssen Biotech, Inc. $76 5 payments
  10. Celgene Corporation $65 3 payments
  11. Other $434 28 payments

Every payment, record by record

What the payments were for General payments · program year 2019
  1. Food and Beverage $2,322 144 payments
Products named General payments · program year 2019
  1. Enbrel $467 34 payments
  2. Prolia $310 19 payments
  3. HUMIRA $272 16 payments
  4. Cimzia $166 11 payments
  5. EVENITY $139 3 payments
  6. ACTHAR $138 7 payments
  7. COSENTYX $136 9 payments
  8. Tymlos $116 2 payments
  9. TALTZ $115 14 payments
  10. KEVZARA $98 5 payments
  11. Other $665 41 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

144 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2019

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record